For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
Mitomycin C market, Mitomycin C is an antibiotic which acts as a double-stranded DNA alkylating agent. It covalently crosslinks DNA, inhibiting DNA synthesis and cell proliferation It acts by way of reductive activation either through low pH or NAD(P)H:quinone oxidoreductase (DT-diaphorase) or NADH cytochrome c reductase (Mao et al.; Cummings et al.).
Scope of the Report:
In the last several years, Global market of Mitomycin C was experienced an upward trend rapidly, with an average growth rate of 4.76%. In 2016, Global Revenue of Mitomycin C is nearly 119.83 M USD; the actual production is about 17370 K Unit.
The global average price of Mitomycin C is in the increasing trend, from 6.30 USD/Unit in 2012 to 6.90 USD/Unit in 2016. With the situation of global economy, prices will be in increasing trend in the following five years.
The classification of Mitomycin C includes 2 Mg, 10 Mg, 40 Mg, and others. The proportion of 2 Mg in 2016 is about 41.5%, and the proportion is in decreasing trend from 2012 to 2016.
Mitomycin C is widely used in Cancer Treatment, Ophthalmic Use, and other field. The most proportion of Mitomycin C is Cancer Treatment, and the proportion in 2016 is 69%. The trend of Cancer Treatment is decreasing.
Japan is the largest supplier of Mitomycin C, with a production market share nearly 26.5% in 2016. India is the second largest supplier of Mitomycin C Media, enjoying production market share nearly 25% in 2016.
North America is the largest consumption place, with a consumption market share nearly 36% in 2016. Following North America, Europe is the second largest consumption place with the consumption market share of 32.6%.
Market competition is not intense. Kyowa-kirin, Intas Pharmaceuticals, Teva, Bristol-Myers Squibb, Aspen, Speciality European Pharma, etc. are the leaders of the industry.
The worldwide market for Mitomycin C is expected to grow at a CAGR of roughly -2.3% over the next five years, will reach 100 million US$ in 2024, from 120 million US$ in 2019, according to a new GIR (Global Info Research) study.
This report focuses on the Mitomycin C in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Market Segment by Manufacturers, this report covers
- Kyowa-kirin
- Intas Pharmaceuticals
- Teva
- Bristol-Myers Squibb
- Aspen
- Speciality European Pharma
- Alkem Laboratories
- Varifarma
- APOGEPHA
Market Segment by Regions, regional analysis covers
- North America (United States, Canada and Mexico)
- Europe (Germany, France, UK, Russia and Italy)
- Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
- South America (Brazil, Argentina, Colombia etc.)
- Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
- 2 Mg
- 10 Mg
- 40 Mg
- Other
Market Segment by Applications, can be divided into
- Cancer Treatment
- Ophthalmic Use
- Others
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Mitomycin C product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top manufacturers of Mitomycin C, with price, sales, revenue and global market share of Mitomycin C in 2017 and 2018.
Chapter 3, the Mitomycin C competitive situation, sales, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Mitomycin C breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2014 to 2019.
Chapter 5, 6, 7, 8 and 9, to break the sales data at the country level, with sales, revenue and market share for key countries in the world, from 2014 to 2019.
Chapter 10 and 11, to segment the sales by type and application, with sales market share and growth rate by type, application, from 2014 to 2019.
Chapter 12, Mitomycin C market forecast, by regions, type and application, with sales and revenue, from 2019 to 2024.
Chapter 13, 14 and 15, to describe Mitomycin C sales channel, distributors, customers, research findings and conclusion, appendix and data source.